Skip to main content
. 2018 Aug 13;9:1867. doi: 10.3389/fimmu.2018.01867

Figure 3.

Figure 3

Peripheral blood CD8+ T cells exhibit a significant and sustained reduction in CX3CR1 surface expression following treatment with recombinant fractalkine. (A) Frequencies of CX3CR1+ cells, as a percentage of CD8+ T cells (left) and CD4+ T cells (right) following; treatment with M199 media alone (NT) or 30 ng/ml of recombinant fractalkine for 2 h (n = 17); (B) representative dot plots of CX3CR1 expression following treatment with M199 media alone (NT) or 30 ng/ml of recombinant fractalkine for 2 h. (C) Frequencies of CX3CR1+ cells, as a percentage of CD8+ T cells following treatment with M199 media alone (NT) or 30 ng/ml of recombinant fractalkine across a time course of 15 min, 30 min, 1 h, 2 h, or 24 h (n = 4). ***p < 0.001 by paired t tests.